生物活性

Pertuzumab, a humanized monoclonal antibody, is a HER2 dimerization inhibitor for the

treatment of metastatic HER2-positive breast cancer.

體外研究
(In Vitro)

Trastuzumab and Pertuzumab are highly synergistic inhibitors of BT474 breast cancer cell

survival. The combination of trastuzumab and Pertuzumab mediates a loss of up to 60%

of cells at doses in which individual drugs do not alter cell survival. The combination of

trastuzumab and Pertuzumab reduces the percentage of proliferating (S-phase) cells 

by more than 2-fold. A combination of trastuzumab and Pertuzumab inhibits cell

proliferation and survival to a greater degree than does either agent alone.

MCE has not independently confirmed the accuracy of these methods. They are for

reference only.

體內研究
(In Vivo)

In Calu-3 NSCLC xenografts, monotherapy with pertuzumab or trastuzumab is able to

significantly inhibit tumor growth, with treatment-to-control ratios (TCR) of 0.23 and 0.27

respectively. The combination of trastuzumab and pertuzumab produces a dramatically

 enhanced antitumor activity compared with single-agent treatments (TCR 0.05, resulting

in tumor regression and, in 3 of 10 animals, complete tumor remission). Treatment of

KPL-4 breast cancer xenografts with either trastuzumab or pertuzumab inhibits tumor

growth with TCRs of 0.67 and 0.65, respectively. Pertuzumab maintains antitumor activity

after progression on trastuzumab.

MCE has not independently confirmed the accuracy of these methods. They are for

reference only.

分子量

145175.18

CAS 號

380610-27-5

中文名稱

帕妥株單抗

儲存方式

   Please store the product under the recommended conditions in the Certificate of Analysis.